Corneal Toxicity in Patients Receiving Antibody–Drug Conjugates for the Treatment of Cancer

Download All
Learn from experts about the monitoring and management recommendations for corneal events associated with antibody–drug conjugates used to treat patients with cancer. Review expert insights in a clinical commentary along with downloadable slides, and on-demand webcast adapted from a live CCO webinar.
Asim V. Farooq, MD
Joann Kang, MD
Paul G. Richardson, MD

Downloadable Slidesets

Download this slideset based on the content from a live satellite symposium with an overview of how treatment with antibody–drug conjugates can cause ocular toxicity for patients with cancer.

Asim V. Farooq, MD Released: November 12, 2021

Download this slideset based on the content from a live satellite symposium with a case study of the antibody–drug conjugate belantamab mafodotin and the potential for ocular toxicity while receiving this treatment for myeloma.

Paul G. Richardson, MD Released: November 12, 2021

Download this slideset based on the content from a live satellite symposium on how to best manage ocular toxicity resulting from therapy with antibody–drug conjugates for patients with cancer.

Joann Kang, MD Released: November 12, 2021

Gain key clinical insights fast, with this short slideset from CCO on key considerations for recognizing and managing ocular toxicities associated with antibody–drug conjugates.

Asim V. Farooq, MD Joann Kang, MD Paul G. Richardson, MD Released: November 29, 2021
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
GlaxoSmithKline

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue